Biological agent for assisting in reducing uric acid and production method

A biopharmaceutical and production method technology, which is applied in the field of uric acid reduction, can solve problems such as slow metabolism, acidification of body fluids, and slow drug effect, and achieve the effects of preventing gouty inflammation, improving kidney function, and reducing cytotoxicity

Inactive Publication Date: 2022-05-06
深圳德荫堂生物科技有限公司
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0002] Under normal circumstances, there are about 1,200 mg of uric acid in the body, about 600 mg is newly produced every day, and 600 mg is excreted at the same time, which is in a balanced state. However, if the body produces too much uric acid and the excretion mechanism is degraded, the body will retain too much uric acid , causing body fluids to become sour, long-term neglect will lead to gout. In addition, excessive fatigue or insufficient rest can also lead to relatively slow metabolism and lead to gout. The production and excretion speed of uric acid in the normal human body is basically constant, and the uric acid content in body fluids changes It can fully reflect the status of metabolism, immunity and other functions in the

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biological agent for assisting in reducing uric acid and production method
  • Biological agent for assisting in reducing uric acid and production method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] As a preferred technical scheme of the invention, it includes the following weight parts of raw materials: 35 parts of Noni fruit extract, 30 parts of theaflavin, 20 parts of plantain, 10 parts of tamarind extract, 5 parts of white peony, 5 parts of rattan extract, 5 parts of Theanine and 1 part of cordycepin.

[0031] In this embodiment, the raw materials also include kelp extract and tea extract. The mass fraction of kelp extract is 0.5-1.5 and the mass fraction of tea extract is 0.5-1.5. Kelp extract can significantly improve the expression level of urate excretion promoting gene UAT, reduce the expression level of urate reabsorption gene URAT, and significantly reduce the content of serum uric acid on the premise of protecting renal function, The tea extract reacts with alkalized uric acid to promote uric acid excretion, so as to reduce the uric acid value and make the uric acid reducing effect of the composition of the invention better.

Embodiment 2

[0033] As a preferred technical scheme of the invention, it includes the following weight parts of raw materials: 60 parts of Noni fruit extract, 55 parts of theaflavin, 32 parts of plantain, 18 parts of tamarind extract, 8 parts of white peony, 8 parts of rattan extract, 5 parts of Theanine and 3 parts of cordycepin.

[0034] In this embodiment, the raw materials also include kelp extract and tea extract. The mass fraction of kelp extract is 0.5-1.5 and the mass fraction of tea extract is 0.5-1.5. Kelp extract can significantly improve the expression level of urate excretion promoting gene UAT, reduce the expression level of urate reabsorption gene URAT, and significantly reduce the content of serum uric acid on the premise of protecting renal function, The tea extract reacts with alkalized uric acid to promote uric acid excretion, so as to reduce the uric acid value and make the uric acid reducing effect of the composition of the invention better.

Embodiment 3

[0036] As a preferred technical scheme of the invention, it comprises the following raw materials: 50 parts of Noni fruit extract, 45 parts of theaflavin, 26 parts of plantain, 14 parts of tamarind extract, 6 parts of white peony, 6 parts of rattan extract, 4 parts of Theanine and 2 parts of cordycepin.

[0037] In this embodiment, the raw materials also include kelp extract and tea extract. The mass fraction of kelp extract is 0.5-1.5 and the mass fraction of tea extract is 0.5-1.5. Kelp extract can significantly improve the expression level of urate excretion promoting gene UAT, reduce the expression level of urate reabsorption gene URAT, and significantly reduce the content of serum uric acid on the premise of protecting renal function, The tea extract reacts with alkalized uric acid to promote uric acid excretion, so as to reduce the uric acid value and make the uric acid reducing effect of the composition of the invention better.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a biological agent for assisting in reducing uric acid and a production method, and the biological agent comprises the following raw materials in parts by weight: 35-60 parts of morinda citrifolia extract, 10-15 parts of theaflavin, 10-15 parts of semen plantaginis, 10-15 parts of tamarind extract, 10-15 parts of radix paeoniae alba, 10-15 parts of tinospora sinensis merr extract, 10-15 parts of theanine and 10-15 parts of cordycepin. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 30-55 parts of theaflavin, 20-32 parts of semen plantaginis, 10-18 parts of tamarind extract, 5-8 parts of radix paeoniae alba, 5-8 parts of tinospora sinensis merr extract, 2-5 parts of theanine and 1-3 parts of cordycepin. According to the traditional Chinese medicine composition, the semen plantaginis can achieve the effect of reducing blood uric acid by inhibiting synthesis of uric acid, in addition, the semen plantaginis can also reduce cytotoxicity, so that the kidney function of a patient is improved, gouty inflammation can be prevented due to the fact that the concentration of the uric acid level is reduced, the gouty inflammation caused by high uric acid can be treated, and the traditional Chinese medicine composition has a good application prospect. Therefore, the liquid can play a good role, and a better drug effect is obtained.

Description

technical field [0001] The invention relates to the technical field of reducing uric acid, in particular to a biological agent assisting in reducing uric acid and a production method thereof. Background technology [0002] Under normal circumstances, there are about 1200 mg of uric acid in the body, about 600 mg is newly generated every day, and 600 mg is excreted at the same time, which is in a balanced state. However, if there is too much uric acid in the body, it is too late to excrete or the uric acid excretion mechanism is degraded, there will be too much uric acid in the body, resulting in the acidification of human body fluid. If it is ignored for a long time, it will cause gout. In addition, Excessive fatigue or lack of rest can also lead to relatively slow metabolism, leading to the onset of gout. The production and excretion rate of uric acid in normal people is basically constant. The change of uric acid content in body fluid can fully reflect the status of metabolism,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K36/746A61P19/06A61K31/198A61K31/7076A61K31/353
CPCA61K36/746A61K36/68A61K36/48A61K36/71A61K36/65A61K36/59A61K31/198A61K31/7076A61K31/353A61P19/06A61K2236/331A61K2300/00
Inventor 娄国豪张峰铄周鲁帝
Owner 深圳德荫堂生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products